Transcriptomic profiling of human corona virus (HCoV)-229E -infected human cells and genomic mutational analysis of HCoV-229E and SARS-CoV-2

Nehemya Friedman^{1, 2}, Jasmine Jacob-Hirsch^{3,4}, Yaron Drori^{1, 2}, Eyal Eran^{3,4}, Nitzan Kol^{3,4}, Omri Nayshool^{3,4}, Ella Mendelson^{1, 2}, Gideon Rechavi^{3,4} and Michal Mandelboim^{1, 2, *}

¹ Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.

² Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

³ Sheba Cancer Research Center (SCRC), Chaim Sheba Medical Center, Ramat Gan, Israel.

⁴ Wohl Centre for Translational Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel.

* Corresponding author:

E-mail: michalman@sheba.health.gov.il (MM)

Keywords: HCoV-229E, NGS, Transcriptome, Antiviral response, APOBEC, SARS-CoV-2

Abstract

Human coronaviruses (HCoVs) cause mild to severe respiratory infection. Most of the common cold illnesses are caused by one of four HCoVs, namely HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43. Several studies have applied global transcriptomic methods to understand host responses to HCoV infection, with most studies focusing on the pandemic severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome CoV (MERS-CoV) and the newly emerging SARS-CoV-2. In this study, Next Generation Sequencing was used to gain new insights into cellular transcriptomic changes elicited by alphacoronavirus HCoV-229E. HCoV-229E-infected MRC5 cells showed marked downregulation of superpathway of cholesterol biosynthesis and eIF2 signaling pathways. Moreover, upregulation of cyclins, cell

cycle control of chromosomal replication, and the role of BRCA1 in DNA damage response, alongside
downregulation of the cell cycle G1/S checkpoint, suggest that HCoV-229E favors S phase for viral infection.
Intriguingly, a significant portion of key factors of cell innate immunity, interferon-stimulated genes (ISGs)
and other transcripts of early antiviral response genes were downregulated early in HCoV-229E infection. On
the other hand, early upregulation of the antiviral response factor Apolipoprotein B mRNA editing enzyme
catalytic subunit 3B (*APOBEC3B*) was observed. APOBEC3B cytidine deaminase signature (C-to-T) was
previously observed in genomic analysis of SARS-CoV-2 but not HCoV-229E. Higher levels of C-to-T
mutations were found in countries with high mortality rates caused by SARS-CoV-2. APOBEC activity could
be a marker for new emerging CoVs. This study will enhance our understanding of commonly circulating
HCoVs and hopefully provide critical information about still-emerging coronaviruses.

Author summary

Human coronaviruses (HCoVs) generate respiratory tract infections. HCoV-229E is one of four known HCoV
strains that circulate annually in the population for several decades. Beside these, three pandemic CoV
emerged since year 2002, the Severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East
respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2. These three strains attracted most
attention for extensive research and less consideration has been given to the commonly infecting HCoVs. In
this study we use Next generation sequencing analysis to understand global transcriptomic changes in human
host cells following HCoV-229E infection. We found several cellular pathways that change during infection
that involve cholesterol biosynthesis, cell cycle control, DNA replication, DNA repair, innate immune
response and an interesting RNA editing enzyme which could be involve in CoVs pathogenesis.

Introduction

Human coronaviruses (HCoVs), which are enveloped, positive single-stranded RNA (+ssRNA) viruses belonging to the *Coronaviridae* family, are associated with a wide spectrum of respiratory diseases [1, 2]. Thus far, seven types of HCoV have been discovered in humans, the majority (Alphacoronavirus species HCoV-NL63 and HCoV-229E and betacoronavirus species HCoV-HKU1 and HCoV-OC43) being causative agents of community-acquired infections. These HCoV infections occur primarily in the winter-spring season [3-5] [6], however summer epidemics have been detected [7]. The other three HCoVs are the pandemic severe acute respiratory syndrome coronavirus (SARS-CoV), the Middle East respiratory syndrome coronavirus (MERS-CoV) [8] and the newly pandemic SARS-CoV-2 [9].

HCoVs typically exploit three known receptors or O-acetylated sialic acids on the host cell surface to gain entry [10]. Coronaviruses have an exceptionally large ~30 kb genome in polycistronic organization and engage a unique transcription mechanism to generate mRNA [11]. They possess many non-structural proteins (NSPs) that appear to have multiple functions in RNA processing, facilitating viral entry, gene expression and virus release [10]. Many +ssRNA viruses use diverse strategies to subvert and exploit host protein synthesis [12], with one central strategy involving inactivation of the elongation initiation complex by manipulating kinase activities. Indeed, viral replication and protein expression are associated with endoplasmic reticulum (ER) overload and subsequent stress responses which trigger host protein translation shutoff. Coronaviruses have evolved to block or subvert these responses in order to restore ER homeostasis or block apoptosis [13]. Some coronaviruses have evolved to counteract the dsRNA-activated protein kinase (PKR), which prevents translation by phosphorylating elongation initiation factor 2 (eIF2) and upregulating antiviral gene expression, including the production of interferons (IFNs) [10, 14]. Several additional innate immune receptors involved in recognizing RNA viruses activate interferon-stimulated genes (ISGs) and other cellular factors which fight the viral intruders [15].

In the last decade, several studies have focused on host cell transcriptome changes subsequent to HCoV infection. Microarray analysis in human A549 and HuH7 cells found HCoV-229E to attenuate the inducible activity of NF-κB and to restrict the nuclear concentration of NF-κB subunits [16]. Another microarray

analysis of peripheral blood mononuclear cells collected from SARS-CoV patients, described the altered inflammatory and immune genes that may contribute to acute lung injury and imbalance of homeostasis [17]. Differential RNA sequencing analysis comparing SARS-CoV and MERS-CoV–infected human Calu-3 cells showed that both viruses induced a similar activation pattern of recognition receptors and of the interleukin 17 (IL-17) pathway, however, only MERS-CoV downregulated the expression of type I and II major histocompatibility complex genes [18]. Transcriptomic characteristics of SARS-CoV-2 patients identified excessive cytokine release, activation of apoptosis and of the p53 signaling pathway [19]. Global transcriptomic sequencing to shed light on the influence of common circulating HCoVs on host cells is lacking. Thus, this study used RNA-next generation sequencing (NGS) to track the transcriptomic changes in human MRC-5 cells following infection with HCoV-229E.

Results

RNA extracted at various time points following infection of MRC5 with HCoV-229E, demonstrated rapid viral propagation inside the host cells, reaching maximal levels at 24 HPI and remained stable for several days (Fig 1A). Viral copies began to emerge in the supernatant at 24 HPI and gradually increased over time (Fig 1B). At 96 HPI, MRC5 cell counts began to decline and the cells were not viable a day later. In parallel to the high replication rate of HCoV-229E, a robust change in the MRC5 transcriptome was observed, with 1465 transcripts already showing a >2-fold change at 6 HPI ('early genes') as compared to uninfected cells. The number of active genes continued to increase as infection progressed, until it reached over 5000 transcripts at 48-72 HPI (Fig 1C).

Prediction of canonical pathways based on the most significant gene enrichment included eIF2 signaling, cell cycle control of chromosomal replication, cholesterol biosynthesis superpathway, BRCA1-associated DNA damage response and other cell cycle checkpoint regulation pathways (Fig 2A). More specifically, 205 gene annotations in the NGS analysis were categorized in the eIF2 signaling pathway, of which 64.88% genes were active/inactive in MRC5 cells. At early stages of infection, considerable downregulation of the eIF2 signaling pathway was observed in MRC5 cells, a trend which increased as infection progressed (Fig 2, B-I). In this pathway, over 80 genes which are coding to ribosomal protein subunits (RPLs and RPSs) were downregulated

during infection (data not presented). The cell cycle control of chromosomal replication pathway includes genes that are involved in the strict control of DNA origin replication points. In our analysis, 57 genes were annotated to this pathway in IPA software, of which 64.91% were active/inactive in MRC5 cells. Genes in this pathway were upregulated mostly at the early stages of HCoV-229E infection (22 genes at 6 HPI), but lightly active during the late stages of infections (Fig 2, B-II). Two of the most significantly upregulated early genes in this pathway were *ORC1* and *CDC6*, both of which initiate assembly of a pre-replication complex at DNA replication origins [20]. In the cholesterol biosynthesis pathway, 18 genes were downregulated in MRC5 cells, 15 of which at 6 HPI (Fig 2, B-III). During infection, the BRCA1 and DNA damage response pathway was active (48.75% of 80 genes) in MRC5 cells. Many genes in the pathway were upregulated within 6-24 HPI, followed by a gradual decline in gene expression as infection persisted (Fig 2, B-IV). To confirm the data of RNA-Sequencing, MRC5 cells were infected with HCoV-229E and total RNA was extracted and analyzed by qRT-PCR for the detection of several selected mRNAs with differential expression (Fig 2C). Relative gene expression was calculated for 2 transcripts in the cell cycle control of chromosomal replication pathway, *ORC1* and *CDK1* mRNA (Fig 2C- I and II respectively) and one eIF2 pathway factor, *ATF3* mRNA (Fig 2C- III).

Next, expression of genes involved in antiviral response were analyzed. In a database of 319 genes involved in "antiviral response", 256 genes were found in our NGS analysis, of which 105 were active in MRC5 cells during HCoV-229E infection. Strikingly, as shown in figure 3A, 82% of the antiviral genes were downregulated at 6 HPI, and 65% were downregulated genes at 24 HPI. Only at 48-72 HPI did the profile change, with 58% of the genes showing upregulated levels as compared to control cells (Fig 3A). The temporal expression of 23 early activated antiviral genes (6 HPI), as shown in figure 3B, indicates that most of the downregulated genes remained inactive (below 2 fold change) during infection. In general, these genes included a cluster of ISGs, e.g., the transcription factors interferon regulatory factor 1 and 2 (*IRF1* and *IRF2*) and interferon-induced protein with tetratricopeptide repeats (*IFITs*) family members, a major branch of the immune antiviral response [21, 22]. Furthermore, an early regulator of the response to viral RNA detection, *DHX58* (also known as *LPG2* or *RIG-I-like receptor 3 (RLR-3)*), was downregulated (-2.25 fold) following HCoV-229E infection, as was suppressor of cytokine signaling 1 (*SOCS1*) (-2.09 fold). *SOCS1* is involved in

negative regulation of cytokines that signal through the JAK/STAT pathway which induces expression of IFN-stimulated genes [23, 24]. PCR analysis of *CLU* transcript, one of the early antiviral response genes (Fig 3B), validated the trend of expression observed in the NGS analysis (Fig 3C).

Apolipoprotein B mRNA editing enzyme catalytic subunit 3B (*APOBEC3B*) was upregulated in early antiviral responses in infected MRC5 cells (Fig 3B). APOBEC3 proteins play essential roles in innate immunity by deaminating cytidine in RNA (C-to-U) and/or DNA (C-to-T), restricting foreign viral RNA/DNA [25]. Mutational analysis suggests that pandemic corona viruses show a pattern of *APOBEC* activity in infected cells [26]. Thus we analyzed genomic sequences of HCoV-229E and of the most recent outbreak of SARS-CoV-2 in search of variant viruses showing characteristics of APOBEC editing activity. We downloaded 303 partial and complete genomes of HCoV-229E obtained from clinical samples (From the ViPR database) and showed that C-to-T mutations occurred as frequently as T-to-C mutations (Fig 4A). However, a first analysis of broncho-alveolar lavage fluids derived from two Wuhan patients showed nucleotide changes that may be signatures of RNA editing [26]. In a larger analysis, using the Global Initiative for Sharing All Influenza Data GISAID SARS-CoV-2 sequence database, Korber et al. found a distinct bias for C-to-T mutations (47%) in the spike protein [27]. In order to further characterize the mutation in the whole genomic sequence of the SARS-CoV-2, 16600 SARS-CoV-2 sequences from different origins were downloaded from the hCoV-19 database and compared; 41% of the variation between the sequences were C-to-T (Fig 4B). Higher correlation was found between C-to-T occurrences and geographic regions characterized with high mortality as compared to lower mortality ($R^2=0.222$, $R^2=0.065$ respectively) (Fig 4C-D), suggesting that the new emerging CoV may use the APOBEC nucleotide editing activity to increase its virulence.

Discussion

This study sought to shed light on host transcriptome responses to common infecting HCoVs, using NGS and bioinformatics tools. More specifically, it aimed to examine major transcriptomic changes occurring over several cycles of HCoV-229E infection in human host cells. Several cellular pathways that were affected early in infection were identified, i.e., eIF2 signaling, cell cycle, cholesterol biosynthesis, BRCA1-associated DNA damage response and cellular innate immune factors.

The fluidity of membranes is dependent on the presence and structure of specific lipids and sterols. While cholesterol increases membrane fluidity by interfering with the packing of acyl chains, it can also reduce the flexibility of neighboring unsaturated acyl chains [28, 29]. Viruses may remodel lipid metabolism and membrane structure to form a microenvironment suitable for infection [29]. Lipidomic analyses have uncovered a striking rearrangement of fatty acids and phospholipids in the cellular membrane upon HCoV-229E and MERS-CoV infection [30, 31]. The current NGS analysis indicated that the cholesterol biosynthesis pathway is inhibited in multiple stages following HCoV-229E infection (Fig 2, A and B-III). Cholesterol can promote coronavirus murine hepatitis virus (MHV) entry to the cells [29]. When cholesterol was depleted by methyl β -cyclodextrin (M β CD) or supplemented in growth media, it reduced or increased cells susceptibility to MHV respectively [32]. These various cholesterol levels are correlated with S-protein-mediated membrane fusion rather than binding activities [32]. HCoV-229E binds to CD13 in lipid rafts and enters the cell through caveolae [33]. Depletion of plasma membrane cholesterol by M β CD disrupted the co-localization of HCoV-229E and caveolin-1 and decreased the intracellular occurrence of HCoV-229E [33]. Both SARS-CoV-1 and SARS-CoV-2 S proteins bind the host cell receptor ACE2 [34]. This receptor is localized in cholesterol-rich microdomains, which are important for the efficient interaction of the S protein with ACE2 [35]. Depletion of plasma membrane cholesterol with M β CD in Vero E6 cells relocalized the raft-resident marker caveolin-1 as well as ACE2 to a non-raft environment, and inhibited infectivity of the virus [36]. Intriguingly, cholesterol depletion by pretreatment of Vero E6 cells with M β CD reduced the release of SARS-CoV particles and the levels of viral mRNAs were significantly decreased. However, cholesterol depletion at the post-entry stage (3 HPI) caused only a limited effect on virus particle release [37]. It remains to be determined if inhibition of the cholesterol biosynthesis superpathway in MRC5 cells is an attempt of the host to interfere with HCoV-229E infection, or a response of the virus to establish a suitable environment for infection. If the cholesterol biosynthesis superpathway is inhibited, the basic acetyl-CoA molecule could be directed to other metabolic or synthetic pathways.

Acetyl-CoA is a major substrate used in the transfer of acetyl groups to lysine residues of histones, which results in increased accessibility of chromatin to DNA-binding proteins to the exposed sites, where they can then activate gene transcription [38]. In HCoV-229E-infected MRC5 cells, changes in several pathways that

could be linked together were observed, i.e., cell cycle regulation, control of chromosomal replication and the role of BRCA1 in DNA damage response. Cell cycle control of the chromosomal replication pathway refers to the strict control of the chromosomal origin of replication. This pathway includes the six-subunit origin recognition complex (ORC), cell division control protein 6 (Cdc6) AAA+ ATPase, minichromosome maintenance (MCM) protein complex, cyclin-dependent protein kinases (CDKs) and others [39]. Marked upregulation of this pathway was observed in early stages of HCoV-229E infection. Exploitation of host ORC has been extensively described in Epstein–Barr virus (EBV) infection, where the virus utilizes its own EBNA1 to recruit host replication initiation machinery [40, 41]. Similarly, coronaviruses manipulate the cell at various stages, which can differ between the specific coronaviruses and even between host cell types [10]. In the present analysis, upregulation of cyclins and cell cycle regulation pathway was observed, together with downregulation of checkpoint regulation Growth 1 (G1) to Synthesis (S) phases, implying that cells enter the DNA synthesis phase. Functional annotation analysis supported these observations, where "Interphase", "Segregation of chromosomes", "G1/S phase transition", "S phase" and "M phase" annotations were upregulated at 6 HPI in MRC5 cells (data not presented, IPA software). Many DNA and RNA viruses are known to manipulate cell cycle at different stages, in efforts to increase the efficiency of virus replication by subverting host-cell functions [42]. This action is not restricted to DNA viruses or retroviruses, which primarily replicate in the nucleus, but also RNA viruses, which mainly replicate in the cytoplasm [43]. For instance, infection with measles, a negative ssRNA viruses, leads to cell arrest in G0 stage [44] and simian parainfluenza virus 5 (SV5) promotes prolonged G1 and G2 phases [45]. The positive-ssRNA avian coronavirus infectious bronchitis virus (IBV) was shown to induce cell cycle arrest at both S and G2/M phases for the enhancement of viral replication and progeny production [46-48]. Betacoronavirus MHV infection causes decreased hyperphosphorylation of the retinoblastoma protein (pRb), resulting in arrest of cell cycle progression from G1 to S [49]. Transient expression of the SARS-CoV 3a structural protein inhibits cell growth and prevents 5-bromodeoxyuridine incorporation, suggesting that it inhibits cell cycle progression [50]. The current analysis suggests that HCoV-229E causes cell cycle arrest mainly in S phase and benefits from this cellular recruitment for chromosomal replication.

As MRC5 cells enter DNA replication stage during HCoV-229E infection, mutations can occur. Accordingly, upregulation of BRCA1-associated DNA damage response was observed. To avoid passage of accumulated DNA damage to daughter cells, cell cycle checkpoints are activated to regulate cell growth and division, allowing cells to repair the damage before resuming cell cycle progression [51]. DNA damage activates the kinases ATM, ATR and CHK2, which, in turn, activate BRCA1 by phosphorylation [52]. The tumor repressor BRCA1 is recruited to DNA damage sites, promotes DNA damage checkpoint activation and DNA damage repair [51, 53]. BRCA1 has been suggested to be responsible for or involved in the activation for G1/S, S-phase and G2/M checkpoints [53-56]. Activation of the ATR-dependent cellular DNA damage response is one of the mechanisms exploited by IBV to induce cell cycle S-phase arrest [46]. Activation of the cellular DNA damage response by the gammacoronavirus infectious bronchitis virus (IBV) causes cell cycle arrest in the S phase, thereby upregulating DNA replication factors in the cytoplasm, which are exploited for viral replication [10, 46].

Translation is a key step in the regulation of gene expression and one of the most energy-consuming processes in the cell. In homeostasis, the eIF2 machinery actively participates in the regulation of protein synthesis and its dysregulation is thought to contribute to pathological conditions [57]. While proper synthesis is crucial for the innate antiviral immune response, viruses rely on the host translation machinery and directly interfere with the function of transcription factors or with signaling pathways that regulate translation, to favor synthesis of viral proteins [12]. Coronaviruses modulate host protein synthesis through different mechanisms, which contributes to their pathogenicity [10]. Like other viruses, coronaviruses overload the ER with the production of viral proteins, thus triggering an ER stress response. SARS-CoV, MHV, IBV and TGEV intervene with ER stress and eIF2 regulators to ensure continuous production of functional viral proteins [13]. In the current study, downregulation of the eIF2 signaling pathway occurred at early stages of HCoV-229E infection. This is assume to be in response to the robust growth of HCoV-229E inside the cells (Fig 1A), which presumably causes ER overload at early stages of infection, thereby triggering a stress response, including manipulation of eIF2 signaling (Fig 2, B-I), as reported for other CoVs [13].

Viral dsRNA and 5'-triphosphate-RNA molecules are present in the cytosol and recognized by intracellular sensors. These sensors activate signaling pathways that generally activate IFN-regulatory factors (IRFs) and

NF- κ B. The latter triggers the excretion of cytokines and Type-I IFN, which activate JAK-STAT signaling, 235
which, in turn, induces expression of antiviral ISGs [58, 59]. Since the present NGS analysis identified broad 236
downregulation of ISG transcripts (Fig 3), it can be assumed that the HCoV infection interfered with upstream 237
regulators of IFN transcription. Indeed, downregulation of IRF1 and IRF2 transcription factors (Fig 3B), 238
which are responsible for inducing the expression of IFNs and pro-inflammatory cytokines [60], and which 239
are necessary for positive regulation of Toll-like receptor 3 transcription that recognizes dsRNA [22, 61-63], 240
was observed. Similarly microarray analysis of an acute case of SARS-CoV revealed upregulation of pro- and 241
anti-inflammatory signals and downregulation of many IFN-stimulated genes [17]. Upregulation of 242
APOBEC3B was demonstrated in the early stages of HCoV-229E infection (Fig 3B). Induction of APOBEC3 243
family members is augmented by IFN- α [64]. APOBEC3B is a DNA cytidine deaminase that prevents 244
interspecies DNA transmission by conversion of cytosines of foreign DNA to uracil, leading to 245
hypermutations [65-67]. RNA editing activity of this cytidine deaminase was first demonstrated in human 246
immunodeficiency virus (HIV) and later in measles, mumps and respiratory syncytial virus (RSV) [68, 69]. 247
Upregulation of several APOBEC3 transcripts was observed in cultured human airway epithelium (HAE) cells 248
following HCoV-NL63 infection. More specifically, three APOBEC family proteins (A3C, A3F and A3H) 249
inhibited viral infection in vitro but did not cause hypermutation of the HCoV-NL63 genome [70]. Viral RNA 250
sequencing and mutational analysis has suggested that both APOBEC and adenosine deaminase acting on 251
RNA (ADAR) deaminases are involved in SARS-CoV, MERS-CoV and SARS-CoV-2 genome editing [26]. 252
The present analysis showed that the mutational imprint of APOBEC proteins is less distinct in commonly 253
infecting HCoVs, which have been circulating for decades [70] (Fig 4). However, APOBEC proteins may 254
cause antigenic drift that shapes the spread of new pandemic CoVs [26] (Fig 4). 255
256
This work used NGS and bioinformatics approaches to demonstrate the influence of HCoV-229E on the host 257
cell transcriptome. Several pathways that were altered were discussed, mainly involving alterations of the host 258
cell cycle regulation, metabolic processes, protein synthesis machinery and cellular innate antiviral responses. 259
This study provides important data and expands our current understanding of the pathology and treatment 260
targets of common HCoVs and newly emerging Coronaviridae. 261

	262
Methods	263
Viruses and cell cultures	264
HCoV-229E virus was purchased from ATCC (VR740™) along with its recommended human host cell lines	265
MRC5. Cells were grown in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% fetal calf	266
serum (FCS). After a 24-hour culture to 80-90% confluency, cells were infected with 0.01 multiplicity of	267
infection (MOI) of virus. HCoV-229E was grown in a humidified incubator with 5% CO ₂ , at 35°C. Cells and	268
virus were incubated for 2-7 days as per the manufacturer recommendations.	269
RNA extraction and preparation	270
Total RNA was extracted at 0, 6, 24, 48, 72 and 96 hours post-HCoV-229E infection, using NucliSENS®	271
easyMag®, according to the manufacturer's protocol. At each time point, three biological repeats were tested.	272
All RNA samples were treated with RQ1 RNase-free DNaseI (Promega, USA), according to the	273
manufacturer's protocol. RNA quality was assessed using the Agilent High Sensitivity RNA ScreenTape for	274
TapeStation System (Agilent Technologies, Germany).	275
Real-time quantitative reverse transcription–polymerase chain reaction (qRT-PCR)	276
Viral load in both supernatants and cells was determined as described by Dare et al. [71]. Validation of gene	277
expression was performed using SensiFAST™ SYBR® Lo-ROX One-Step Kit, according to the	278
manufacturer's instructions (Bioline Reagents Ltd). The primers used for validations were as follow: <i>ORC1</i> :	279
F-5'-AGAGCCATCCTCGCAGAGTT, R-5'-GCAGTCCCTCCATTCTGCAC; <i>CLU</i> : F-5'-	280
GAAGAGCGCAAGACACTGCT, R-5'-CAGACGCGTGCGTAGAACTT; <i>CDK1</i> : F-5'-	281
TTGGCCTTGCCAGAGCTTTT, R-5'-CGAGCTGACCCAGCAATAC. <i>ATF3</i> : F-5'-	282
CGGAGTGCCTGCAGAAAGAG, R-5'-GTGGGCCGATGAAGGTTGAG. Relative gene expression was	283
calculated using the 2 ^{-ΔΔCt} method [72].	284
RNA preparation, sequencing and data analysis	285

For NGS analysis the RNA samples (>8 RNA integrity number (RIN)) were prepared using the Illumina TruSeq RNA Library Preparation Kit v2 and sequenced in Illumina HiSeq 2500 Sequencer. Software and applications used for sequencing and data analysis were as follows: library quality control: FASTQC version 0.11.5, quality and adapter trimming: trim_galore (uses cutadapt version 1.10), mapping: Tophat2 version 2.1.0 (uses Bowtie2 version 2.2.6), gene counting: HTseq-count version 0.6.1/0.11.2, normalization and differential expression analysis: DESeq2 R package version 1.18.1. Sequencing and quality control were conducted by the Technion Genome Center (TGC). RNA-Seq library is available at the Gene Expression Omnibus (GEO) repository, accession number GSE155986. Data analysis was performed using QIAGEN Ingenuity Pathway Analysis (QIAGEN IPA) software. Transcriptomic reads at each time point were compared to the uninfected cells. Canonical pathways were analyzed with highest $-\log(p\text{-value})$ (significance of gene enrichment for any given pathway) and highest z-score (directional effect). Diseases and Functions Analysis in IPA software predicts cellular processes and biological functions based on gene expression and predicts directional change on that effect (IPA manual). A database of 319 "antiviral response"-annotated genes were pooled from the IPA database and compared to the collected transcriptome dataset. TIBCO Spotfire version 7.7.0.39 was used for data analysis, filtering and visualization, including heatmap generation. Whole genomic sequences of the SARS-CoV-2 were downloaded from the hCoV-19 data base (GSAID; more than 16600 sequences, at May 12 2020). Sequences of HCoV-229E were obtained from the NIAID Virus Pathogen Database and Analysis Resource (ViPR) [73] through the web site at <http://www.viprbrc.org/>. For genomic analysis we used the bioinformatics toolkit Augur (<https://nextstrain-augur.readthedocs.io/en/stable/>).

Author Contributions

NF performed the experiments, data analysis and prepared the manuscript. JJH performed data analyses. YD, EM and GR provided scientific assistance. MM provided scientific assistance and critically reviewed the manuscript.

	310
Conflicts of Interest	311
The authors declare no conflict of interest.	312
This work was performed in partial fulfillment of the requirements for a Ph.D. degree of Nehemya Friedman,	313
Sackler Faculty of Medicine, Tel Aviv University, Israel.	314
References	315
1. Geller, C., M. Varbanov, and R.E. Duval, <i>Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies</i> . <i>Viruses</i> , 2012. 4 (11): p. 3044-68.	316
2. Razuri, H., et al., <i>Human Coronavirus-Associated Influenza-Like Illness in the Community Setting in Peru</i> . <i>Am J Trop Med Hyg</i> , 2015. 93 (5): p. 1038-40.	318
3. Gerna, G., et al., <i>Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients</i> . <i>J Med Virol</i> , 2006. 78 (7): p. 938-49.	320
4. Gerna, G., et al., <i>Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients</i> . <i>J Clin Virol</i> , 2007. 38 (3): p. 244-50.	323
5. Vabret, A., et al., <i>Human (non-severe acute respiratory syndrome) coronavirus infections in hospitalised children in France</i> . <i>J Paediatr Child Health</i> , 2008. 44 (4): p. 176-81.	325
6. Gaunt, E.R., et al., <i>Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method</i> . <i>J Clin Microbiol</i> , 2010. 48 (8): p. 2940-7.	327
7. Friedman, N., et al., <i>Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1</i> . <i>Viruses</i> , 2018. 10 (10).	330
8. Andrew King, Elliot Lefkowitz, Michael J. Adams, Eric B. Carstens. <i>Virus Taxonomy - 1st Edition</i> . Elsevier, 2017.	332
9. Viruses, C.S.G.o.t.I.C.o.T.o., <i>The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</i> . <i>Nat Microbiol</i> , 2020. 5 (4): p. 536-544.	334
10. de Wilde, A.H., et al., <i>Host Factors in Coronavirus Replication</i> . <i>Curr Top Microbiol Immunol</i> , 2018. 419 : p. 1-42.	336
11. Sola, I., et al., <i>Continuous and Discontinuous RNA Synthesis in Coronaviruses</i> . <i>Annu Rev Virol</i> , 2015. 2 (1): p. 265-88.	338
12. Walsh, D. and I. Mohr, <i>Viral subversion of the host protein synthesis machinery</i> . <i>Nat Rev Microbiol</i> , 2011. 9 (12): p. 860-75.	340
13. Fung, T.S., Y. Liao, and D.X. Liu, <i>Regulation of Stress Responses and Translational Control by Coronavirus</i> . <i>Viruses</i> , 2016. 8 (7).	342
14. Wang, X., et al., <i>Inhibition of protein kinase R activation and upregulation of GADD34 expression play a synergistic role in facilitating coronavirus replication by maintaining de novo protein synthesis in virus-infected cells</i> . <i>J Virol</i> , 2009. 83 (23): p. 12462-72.	344
15. Jensen, S. and A.R. Thomsen, <i>Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion</i> . <i>J Virol</i> , 2012. 86 (6): p. 2900-10.	347
16. Poppe, M., et al., <i>The NF-κB-dependent and -independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells</i> . <i>PLoS Pathog</i> , 2017. 13 (3): p. e1006286.	349

17. Yu, S.Y., et al., *Gene expression profiles in peripheral blood mononuclear cells of SARS patients*. World J Gastroenterol, 2005. **11**(32): p. 5037-43. 351
18. Josset, L., et al., *Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus*. mBio, 2013. **4**(3): p. e00165-13. 353
19. Xiong, Y., et al., *Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients*. Emerg Microbes Infect, 2020. **9**(1): p. 761-770. 355
20. Speck, C., et al., *ATPase-dependent cooperative binding of ORC and Cdc6 to origin DNA*. Nat Struct Mol Biol, 2005. **12**(11): p. 965-71. 357
21. Mears, H.V. and T.R. Sweeney, *Better together: the role of IFIT protein-protein interactions in the antiviral response*. J Gen Virol, 2018. **99**(11): p. 1463-1477. 359
22. Sun, L., et al., *HCFC2 is needed for IRF1- and IRF2-dependent*. J Exp Med, 2017. **214**(11): p. 3263-3277. 361
23. Frantsve, J., et al., *Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation*. Mol Cell Biol, 2001. **21**(10): p. 3547-57. 363
24. Nan, Y., C. Wu, and Y.J. Zhang, *Interplay between Janus Kinase/Signal Transducer and Activator of Transcription Signaling Activated by Type I Interferons and Viral Antagonism*. Front Immunol, 2017. **8**: p. 1758. 366
25. Conticello, S.G., *The AID/APOBEC family of nucleic acid mutators*, in *Genome Biol*. 2008. p. 229. 369
26. Giorgio, S.D., et al., *Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2*. 2020. 370
27. Korber, B., et al., *Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2*. 2020. 372
28. Yeagle, P.L., *Cholesterol and the cell membrane*. Biochim Biophys Acta, 1985. **822**(3-4): p. 267-87. 374
29. Holthuis, J.C. and A.K. Menon, *Lipid landscapes and pipelines in membrane homeostasis*. Nature, 2014. **510**(7503): p. 48-57. 375
30. Yan, B., et al., *Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication*. Viruses, 2019. **11**(1). 377
31. Mayer, K.A., et al., *Hijacking the Supplies: Metabolism as a Novel Facet of Virus-Host Interaction*. Front Immunol, 2019. **10**: p. 1533. 379
32. Thorp, E.B. and T.M. Gallagher, *Requirements for CEACAMs and cholesterol during murine coronavirus cell entry*. J Virol, 2004. **78**(6): p. 2682-92. 381
33. Nomura, R., et al., *Human coronavirus 229E binds to CD13 in rafts and enters the cell through caveolae*. J Virol, 2004. **78**(16): p. 8701-8. 383
34. Sturley, S., et al., *Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity*. J Lipid Res, 2020. 385
35. Glende, J., et al., *Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2*. Virology, 2008. **381**(2): p. 215-21. 387
36. Lu, Y., D.X. Liu, and J.P. Tam, *Lipid rafts are involved in SARS-CoV entry into Vero E6 cells*. Biochem Biophys Res Commun, 2008. **369**(2): p. 344-9. 390
37. Li, G.M., et al., *Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle*. Microbes Infect, 2007. **9**(1): p. 96-102. 392
38. Burgio, G., M.C. Onorati, and D.F. Corona, *Chromatin remodeling regulation by small molecules and metabolites*. Biochim Biophys Acta, 2010. **1799**(10-12): p. 671-80. 394
39. Diffley, J.F. and K. Labib, *The chromosome replication cycle*. J Cell Sci, 2002. **115**(Pt 5): p. 869-72. 396
40. Yoon, J.H., S. Prakash, and L. Prakash, *Genetic control of translesion synthesis on leading and lagging DNA strands in plasmids derived from Epstein-Barr virus in human cells*. mBio, 2012. **3**(5): p. e00271-12. 397
41. Shen, Z., *The origin recognition complex in human diseases*. Biosci Rep, 2013. **33**(3). 400

42. Bagga, S. and M.J. Bouchard, *Cell cycle regulation during viral infection*. Methods Mol Biol, 2014. **1170**: p. 165-227. 401
43. Emmett, S.R., et al., *The cell cycle and virus infection*. Methods Mol Biol, 2005. **296**: p. 197-218. 403
44. Nanche, D., S.I. Reed, and M.B. Oldstone, *Cell cycle arrest during measles virus infection: a G0-like block leads to suppression of retinoblastoma protein expression*. J Virol, 1999. **73**(3): p. 1894-901. 404
45. Lin, G.Y. and R.A. Lamb, *The paramyxovirus simian virus 5 V protein slows progression of the cell cycle*. J Virol, 2000. **74**(19): p. 9152-66. 406
46. Xu, L.H., et al., *Coronavirus infection induces DNA replication stress partly through interaction of its nonstructural protein 13 with the p125 subunit of DNA polymerase δ* . J Biol Chem, 2011. **286**(45): p. 39546-59. 408
47. Chen, H., et al., *Interaction of the coronavirus nucleoprotein with nucleolar antigens and the host cell*. J Virol, 2002. **76**(10): p. 5233-50. 411
48. Wurm, T., et al., *Localization to the nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt host cell division*. J Virol, 2001. **75**(19): p. 9345-56. 413
49. Chen, C.J. and S. Makino, *Murine coronavirus replication induces cell cycle arrest in G0/G1 phase*. J Virol, 2004. **78**(11): p. 5658-69. 415
50. Yuan, X., et al., *G1 phase cell cycle arrest induced by SARS-CoV 3a protein via the cyclin D3/pRb pathway*. Am J Respir Cell Mol Biol, 2007. **37**(1): p. 9-19. 417
51. Wu, J., L.Y. Lu, and X. Yu, *The role of BRCA1 in DNA damage response*. Protein Cell, 2010. **1**(2): p. 117-23. 419
52. Gudmundsdottir, K. and A. Ashworth, *The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability*. Oncogene, 2006. **25**(43): p. 5864-74. 421
53. Hartwell, L.H. and M.B. Kastan, *Cell cycle control and cancer*. Science, 1994. **266**(5192): p. 1821-8. 423
54. Fabbro, M., et al., *BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage*. J Biol Chem, 2004. **279**(30): p. 31251-8. 424
55. Xu, B., Kim St, and M.B. Kastan, *Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation*. Mol Cell Biol, 2001. **21**(10): p. 3445-50. 426
56. Cuddihy, A.R. and M.J. O'Connell, *Cell-cycle responses to DNA damage in G2*. Int Rev Cytol, 2003. **222**: p. 99-140. 428
57. Roux, P.P. and I. Topisirovic, *Signaling Pathways Involved in the Regulation of mRNA Translation*. Mol Cell Biol, 2018. **38**(12). 430
58. Schoggins, J.W. and C.M. Rice, *Interferon-stimulated genes and their antiviral effector functions*. Curr Opin Virol, 2011. **1**(6): p. 519-25. 432
59. Channappanavar, R. and S. Perlman, *Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology*. Semin Immunopathol, 2017. **39**(5): p. 529-539. 434
60. Gack, M.U., *Mechanisms of RIG-I-like receptor activation and manipulation by viral pathogens*. J Virol, 2014. **88**(10): p. 5213-6. 437
61. Heinz, S., et al., *Species-specific regulation of Toll-like receptor 3 genes in men and mice*. J Biol Chem, 2003. **278**(24): p. 21502-9. 439
62. Ren, G., et al., *Division of labor between IRF1 and IRF2 in regulating different stages of transcriptional activation in cellular antiviral activities*. Cell Biosci, 2015. **5**: p. 17. 441
63. Nhu, Q.M., N. Cuesta, and S.N. Vogel, *Transcriptional regulation of lipopolysaccharide (LPS)-induced Toll-like receptor (TLR) expression in murine macrophages: role of interferon regulatory factors 1 (IRF-1) and 2 (IRF-2)*. J Endotoxin Res, 2006. **12**(5): p. 285-95. 443
64. Peng, G., et al., *Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity*. J Exp Med, 2006. **203**(1): p. 41-6. 446
65. Stenglein, M.D., et al., *APOBEC3 proteins mediate the clearance of foreign DNA from human cells*. Nat Struct Mol Biol, 2010. **17**(2): p. 222-9. 448
66. Yu, Q., et al., *APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication*. J Biol Chem, 2004. **279**(51): p. 53379-86. 450

67. Ooms, M., et al., *APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1*. J Virol, 2012. **86**(11): p. 6097-108. 452
68. Bishop, K.N., et al., *APOBEC-mediated editing of viral RNA*. Science, 2004. **305**(5684): p. 645. 454
69. Fehrholz, M., et al., *The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses*. J Gen Virol, 2012. **93**(Pt 3): p. 565-576. 455
70. Milewska, A., et al., *APOBEC3-mediated restriction of RNA virus replication*. Sci Rep, 2018. **8**(1): p. 5960. 457
71. Dare, R.K., et al., *Human coronavirus infections in rural Thailand: a comprehensive study using real-time reverse-transcription polymerase chain reaction assays*. J Infect Dis, 2007. **196**(9): p. 1321-8. 459
72. Rao, X., et al., *An improvement of the $2^{-(\Delta\Delta CT)}$ method for quantitative real-time polymerase chain reaction data analysis*. Biostat Bioinforma Biomath, 2013. **3**(3): p. 71-85. 461
73. Pickett, B.E., et al., *ViPR: an open bioinformatics database and analysis resource for virology research*. Nucleic Acids Res, 2012. **40**(Database issue): p. D593-8. 463

Figures legends 468

Fig 1. Change in gene expression following HCoV-229E infection. (A-B) Viral propagation of HCoV-229E. MRC5 cells, 24-hour culture to 80-90% confluency, were infected with 0.01 multiplicity of infection (MOI) of HCoV-229E virus. Cells and virus were grown in Eagle's Minimum Essential Medium (EMEM) supplemented with 2% fetal calf serum (FCS) in incubated in a humidified incubator with 5% CO₂, at 35°C. Total RNA was extracted at the indicated hours post infection (HPI) and viral load was determined in both cells (A) or growth media (B) by qPCR analysis. (C) Active transcripts in HCoV-229E –infected MRC5 cells. Total RNA samples of MRC5-infected cells (from section A) were prepared using the Illumina TruSeq RNA Library Preparation Kit v2 and sequenced in Illumina HiSeq 2500 Sequencer. Software and applications used for sequencing and data analysis are specified in the methods. Total number of upregulated (>2 fold change, red bars) or downregulated (<-2 fold change, blue bars) genes at the indicated HPI was calculated by comparing to gene expression to that measured in uninfected cells.

Fig 2. Analysis of canonical pathways in HCoV-229E-infected cells. (A) Canonical pathways enrichment analysis. Analysis was conducted for HCoV-229E-infected MRC5 cells at 6 hours post-infection (HPI) as compared to uninfected cells. Canonical pathways with highest -log p-value (using Benjamini-Hochberg correction) are presented. (B) The number of activated genes was calculated for the eIF2 (I), cell cycle control

of chromosomal replication (II), cholesterol biosynthesis (III) and role of BRCA1 in DNA damage response (IV) pathways. Up- and downregulated pathways are presented in red and blue, respectively. (C) Validation of gene expression. Cells were infected with HCoV-229E and total RNA was extracted and treated as described in the Methods section. Relative gene expression was calculated for *ORC1* (I), *CDK1* (II) mRNA (belong to cell cycle control of chromosomal replication pathway) and *ATF3* (III) mRNA (belongs to eIF2 pathway). Fold-change in transcripts levels, as measured by qPCR analysis (Bars, left Y axis), was compared to the results of the NGS analysis (line, right Y axis).

Fig 3. Expression of genes involved in antiviral response following HCoV-229E infection. (A) Sum of up and downregulated genes in MRC5 cells at each time point post HCoV-229E infection are presented in red and blue, respectively. (B) Early activated antiviral response genes. Genes that were >2 or <-2 fold change in MRC5 cells at 6 hours post HCoV-229E infection are presented in fold change heat map in following HPI. (C) Validation of gene expression. Cells were infected with HCoV-229E and total RNA was extracted and treated as described in the Methods section. Relative gene expression was calculated for *CLU* mRNA. Fold-change in transcripts levels, as measured by qPCR analysis (Bars, left Y axis), was compared to the results of the NGS analysis (line, right Y axis).

Fig 4. APOBEC mutations in HCoV-229E and SARS-CoV-2. (A-B) Mutation analysis of CoVs genomes. Percentage of all types of nucleotide transitions (mutation frequency >0.1) are presented in pie charts for HCoV-229E (A) and SARS-CoV-2 (B). (C-D) Correlation between independently occurring C-to-T events and the number of countries with mutations at the specific site. (C) Correlation in countries with moderate SARS-CoV-2 mortality (<99 deaths per million). (D) Correlation in countries with high SARS-CoV-2 mortality (> 99 deaths per million). Y-axis indicates the number of C-to-T alterations identified as independent events on the phylogenetic tree analysis. X-axis indicates the number of countries in which the event was identified in at least in one corona sample.

A

B

C

Figure-1

A

Canonical pathways enrichment

B

C

Figure-2

A

C

B

MRC5 (fold change vs 0)

Figure-3

Figure-2